Certain identified information has been marked in the exhibit because it is both (i) not material
and (ii) would likely cause competitive harm to the Company, if publicly disclosed.
Double asterisks denote omissions.
This Third Amendment, effective as of the date set forth above the signatures of the parties below (the Third Amendment Effective Date), amends the Exclusive Patent License Agreement having an effective date of November 1, 2013, for M.I.T. Case No. [**] (the Agreement) between the Massachusetts Institute of Technology (M.I.T.), a Massachusetts corporation having its principal office at 77 Massachusetts Avenue, Cambridge, Massachusetts, 02139, USA and Translate Bio Inc. (formerly, RaNA Therapeutics, Inc.) (COMPANY), a Delaware corporation having a principal place of business at 29 Hartwell Ave., Lexington, MA 02421. Capitalized terms used herein and not defined shall have the meanings set forth in the Agreement.
WHEREAS RaNA Therapeutics, Inc., changed its name to Translate Bio, Inc. on June 26, 2017; and
WHEREAS, COMPANY desires to modify the diligence provisions of the Agreement consistent with its ongoing work; and
NOW, THEREFORE, in consideration of the promises and mutual covenants contained herein, the parties hereby agree as follows:
1. Section 3.1, Diligence Requirements, of the Agreement is hereby amended to delete Sections 3.l(d) and 3.l(e) in their entirety and to replace them with the following:
(d) First LICENSED PRODUCT.
(1) [**], COMPANY shall [**]
(2) [**], COMPANY shall [**].
(3) [**], COMP ANY shall [**].
(4) [**], COMPANY shall [**].
(5) [**], COMPANY shall [**].
(6) [**], COMPANY shall [**].